Payment overview · 2025
General Payments
$1,458.91
81 reported records · 20 companies
Healthcare provider profile · identity verified
Gibran B. Naddy, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBIA, TN · NPI 1962470567
Verified facts
What the public records show
CMS Open Payments records show Gibran B. Naddy, M.D. received $1,458.91 in general payments during 2025 across 81 reported records.
Amgen Inc. accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 419 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $264.14 | 18.1% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $247.44 | 17.0% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $200.94 | 13.8% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.55 | 9.5% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $101.94 | 7.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $101.82 | 7.0% | 5 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $60.37 | 4.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.03 | 3.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.38 | 3.7% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.36 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.19 | 2.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.44 | 2.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.28 | 1.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.42 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.98 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.67 | 1.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.62 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.74 | 1.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $14.46 | 1.0% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $6.14 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,458.91 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $200.94 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $161.87 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $154.62 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $154.62 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $138.55 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $102.01 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $101.94 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $85.88 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $71.59 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.36 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $60.37 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.38 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.26 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $7.51 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $6.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 303 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 231 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
303 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
303 | 68 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
231 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
244 | 36 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 22 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
419 | 87 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1077 | 294 |
| Amlodipine Besylate | Amlodipine Besylate | 881 | 253 |
| Pantoprazole Sodium | Pantoprazole Sodium | 687 | 212 |
| Losartan Potassium | Losartan Potassium | 581 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 551 | 138 |
| Potassium Chloride | Potassium Chloride | 537 | 175 |
| Furosemide | Furosemide | 453 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 121 |
| Eliquis | Apixaban | 419 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 381 | 118 |
| Lisinopril | Lisinopril | 377 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 358 | 115 |
| Allopurinol | Allopurinol | 343 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 321 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 321 | 164 |
| Ezetimibe | Ezetimibe | 318 | 102 |
| Omeprazole | Omeprazole | 318 | 94 |
| Mirtazapine | Mirtazapine | 316 | 96 |
| Jardiance | Empagliflozin | 303 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 299 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 287 | 89 |
| Metformin Hcl | Metformin Hcl | 285 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 283 | 82 |
| Trazodone Hcl | Trazodone Hcl | 282 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 276 | 121 |
| Sertraline Hcl | Sertraline Hcl | 262 | 61 |
| Montelukast Sodium | Montelukast Sodium | 251 | 70 |
| Trulicity | Dulaglutide | 244 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 236 | 72 |
| Mounjaro | Tirzepatide | 231 | 40 |
| Carvedilol | Carvedilol | 227 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 77 |
| Buspirone Hcl | Buspirone Hcl | 225 | 57 |
| Meloxicam | Meloxicam | 219 | 71 |
| Pregabalin | Pregabalin | 185 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 183 | 76 |
| Donepezil Hcl | Donepezil Hcl | 180 | 44 |
| Famotidine | Famotidine | 167 | 53 |
| Gabapentin | Gabapentin | 155 | 26 |
| Methylprednisolone | Methylprednisolone | 148 | 122 |
| Prednisone | Prednisone | 128 | 62 |
| Ondansetron Hcl | Ondansetron Hcl | 124 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 25 |
| Warfarin Sodium | Warfarin Sodium | 119 | 15 |
| Celecoxib | Celecoxib | 117 | 41 |
| Metformin Hcl Er | Metformin Hcl | 116 | 42 |
| Alendronate Sodium | Alendronate Sodium | 115 | 36 |
| Azithromycin | Azithromycin | 110 | 100 |
| Tramadol Hcl | Tramadol Hcl | 110 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 20 |
| Glipizide | Glipizide | 103 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 97 | 40 |
| Simvastatin | Simvastatin | 96 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 29 |
| Spironolactone | Spironolactone | 94 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 72 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 88 | 12 |
| Atenolol | Atenolol | 84 | 21 |
| Divalproex Sodium | Divalproex Sodium | 84 | 17 |
| Nystatin | Nystatin | 83 | 45 |
| Torsemide | Torsemide | 83 | 26 |
| Ondansetron Odt | Ondansetron | 82 | 45 |
| Bupropion Xl | Bupropion Hcl | 81 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 20 |
| Linzess | Linaclotide | 80 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 21 |
| Felodipine Er | Felodipine | 74 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 17 |
| Levetiracetam | Levetiracetam | 72 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 72 | 19 |
| Synthroid | Levothyroxine Sodium | 72 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 20 |
| Finasteride | Finasteride | 71 | 25 |
| Nifedipine Er | Nifedipine | 69 | 16 |
| Ozempic | Semaglutide | 68 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 23 |
| Alprazolam | Alprazolam | 64 | 24 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 64 | 18 |
| Meclizine Hcl | Meclizine Hcl | 62 | 37 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | 11 |
| Entresto | Sacubitril/Valsartan | 58 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 37 |
| Digoxin | Digoxin | 55 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 17 |
| Januvia | Sitagliptin Phosphate | 55 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | suppressed |
| Cephalexin | Cephalexin | 53 | 40 |
| Farxiga | Dapagliflozin Propanediol | 51 | 12 |
| Latanoprost | Latanoprost | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Memantine Hcl | Memantine Hcl | 49 | 14 |
| Propranolol Hcl | Propranolol Hcl | 49 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 15 |
| Colchicine | Colchicine | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 18 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 46 | 15 |
| Sucralfate | Sucralfate | 45 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 44 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 14 |
| Verapamil Er | Verapamil Hcl | 42 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | 12 |
| Folic Acid | Folic Acid | 40 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Gemtesa | Vibegron | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | 11 |
| Klor-Con 10 | Potassium Chloride | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | 15 |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 23 |
| Valsartan | Valsartan | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 34 | 14 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 16 |
| Ramipril | Ramipril | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 21 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Anastrozole | Anastrozole | 27 | suppressed |
| Modafinil | Modafinil | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 20 |
| Bydureon Bcise | Exenatide Microspheres | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Lorazepam | Lorazepam | 25 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 17 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 22 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cholestyramine Light | Cholestyramine | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,458.91 · 81 records | Amgen Inc. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GVOKE HYPOPEN, JARDIANCE, KEVEYIS, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LUNA, MOUNJARO, NUPLAZID, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, Sunosi, TRELEGY ELLIPTA, VOQUEZNA, XYWAV, ZENPEP, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error